Read by QxMD icon Read


Luca Ceriani, Sally Barrington, Alberto Biggi, Bogdan Malkowski, Ur Metser, Annibale Versari, Maurizio Martelli, Andrew Davies, Peter W Johnson, Emanuele Zucca, Stéphane Chauvie
The International Extranodal Lymphoma Study Group (IELSG)-37 is a prospective randomized trial assessing the role of consolidation mediastinal radiotherapy after immunochemotherapy to patients with newly diagnosed primary mediastinal large B-cell lymphoma (PMBCL). It is a positron emission tomography (PET) response-guided study where patients obtaining a complete metabolic response on an end-of-therapy PET-computed tomography (CT) scan evaluated by a central review are randomized to receive radiotherapy or no further treatment...
August 22, 2016: Hematological Oncology
Franco Cavalli, Luca Ceriani, Emanuele Zucca
Primary mediastinal large B-cell lymphoma (PMLBCL) is recognized as a distinct disease entity. Treatment outcomes appear better than in other diffuse large B-cell lymphoma (DLBCL) types, partly because of their earlier stage at presentation and the younger age of most patients. If initial treatment fails, however, the results of salvage chemotherapy and myeloablative treatment are poor. The need to avoid relapses after initial therapy has led to controversy over the extent of front-line therapy, particularly whether consolidation radiotherapy to the mediastinum is always required and whether the 18-fluorodeoxyglucose ((18)F-FDG) uptake detected by PET-CT scan can be used to determine its requirements...
2016: American Society of Clinical Oncology Educational Book
Andrés J M Ferreri, Kate Cwynarski, Elisa Pulczynski, Maurilio Ponzoni, Martina Deckert, Letterio S Politi, Valter Torri, Christopher P Fox, Paul La Rosée, Elisabeth Schorb, Achille Ambrosetti, Alexander Roth, Claire Hemmaway, Angela Ferrari, Kim M Linton, Roberta Rudà, Mascha Binder, Tobias Pukrop, Monica Balzarotti, Alberto Fabbri, Peter Johnson, Jette Sønderskov Gørløv, Georg Hess, Jens Panse, Francesco Pisani, Alessandra Tucci, Stephan Stilgenbauer, Bernd Hertenstein, Ulrich Keller, Stefan W Krause, Alessandro Levis, Hans J Schmoll, Franco Cavalli, Jürgen Finke, Michele Reni, Emanuele Zucca, Gerald Illerhaus
BACKGROUND: Standard treatment for patients with primary CNS lymphoma remains to be defined. Active therapies are often associated with increased risk of haematological or neurological toxicity. In this trial, we addressed the tolerability and efficacy of adding rituximab with or without thiotepa to methotrexate-cytarabine combination therapy (the MATRix regimen), followed by a second randomisation comparing consolidation with whole-brain radiotherapy or autologous stem cell transplantation in patients with primary CNS lymphoma...
May 2016: Lancet Haematology
Hyunsoo Cho, Jong Hee Chang, Yu Ri Kim, Soo-Jeong Kim, Haerim Chung, Hyunsung Park, Jung Yeon Lee, Ji Eun Jang, Yundeok Kim, Se Hoon Kim, Woo Ick Yang, Chang-Ok Suh, June-Won Cheong, Yoo Hong Min, Jin Seok Kim
Upfront autologous stem cell transplantation (ASCT) has shown favourable outcome in patients with primary central nervous system lymphoma (PCNSL), but the role of risk-adapted upfront ASCT consolidation has not been evaluated in PCNSL. As PCNSL patients with the International Extranodal Lymphoma Study Group (IELSG) prognostic score ≥2 or those who did not achieve complete response after two courses of induction chemotherapy (non-CR1) have shown inferior outcomes, we retrospectively analysed the role of upfront ASCT in 66 high-risk (IELSG ≥2 and/or non-CR1) younger (age <65 years) immunocompetent PCNSL patients who achieved at least partial response after initial high-dose methotrexate-based chemotherapy...
August 2016: British Journal of Haematology
Vanja Zeremski, Michael Koehler, Thomas Fischer, Enrico Schalk
We aimed to compare the characteristics and outcome of patients treated within the multi-centre German Primary CNS Lymphoma Study Group 1 trial (G-PCNSL-SG-1; TRIAL group) and patients treated outside this clinical trial ("real-life" setting, R-LIFE group). Therefore, we conducted a retrospective single-centre study in order to analyse all patients with newly diagnosed primary CNS lymphoma (PCNSL) treated consecutively in our institution between November 2000 and June 2015. Altogether, 86 patients were analysed (median 68 years)...
April 2016: Annals of Hematology
Michel Meignan
In this issue of Blood, Ceriani et al introduce, in primary mediastinal B-cell lymphoma (PMBCL), a new prognostic factor measured on pretreatment 18F-fluorodeoxyglucose (18FDG)-positron emission tomography (PET)/computed tomography (CT): the total lesion glycolysis (TLG), which is an index of the glucose uptake by the total tumor burden. This paper is part of the International Extranodal Lymphoma Study Group (IELSG) 26 prospective study designed to evaluate the role of PET in the treatment of PMBCL.
August 20, 2015: Blood
Amie E Jackson, Michael Mian, Christina Kalpadakis, Gerassimos A Pangalis, Anastasios Stathis, Elena Porro, Annarita Conconi, Sergio Cortelazzo, Gianluca Gaidano, Armando Lopez Guillermo, Peter W Johnson, Maurizio Martelli, Giovanni Martinelli, Catherine Thieblemont, Ellen D McPhail, Christiane Copie-Bergman, Stefano A Pileri, Andrew Jack, Elias Campo, Luca Mazzucchelli, Kay Ristow, Thomas M Habermann, Franco Cavalli, Grzegorz S Nowakowski, Emanuele Zucca
BACKGROUND: The salivary gland is one of the most common sites involved by nongastric, extranodal marginal zone lymphomas of mucosa-associated lymphoid tissue (MALT). A large series of patients with long-term follow-up has not been documented. This multicenter, international study sought to characterize the clinical characteristics, treatment, and natural history of salivary gland MALT lymphoma. METHODS: Patients with biopsy-confirmed salivary gland MALT lymphoma were identified from multiple international sites...
October 2015: Oncologist
Simona Sammassimo, Giancarlo Pruneri, Giovanna Andreola, Juan Montoro, Sara Steffanoni, Grzegorz S Nowakowski, Sara Gandini, Mara Negri, Thomas M Habermann, Markus Raderer, Zhi-Ming Li, Pier Luigi Zinzani, Patrick Adam, Emanuele Zucca, Giovanni Martinelli
Primary lymphoma of the lung is a rare entity. Clinical features, optimal treatment, role of surgery and outcomes are not well defined, and the follow-up is variable in published data. Clinical data of 205 patients who were confirmed to have bronchus mucosa-associated lymphoid tissue lymphoma from December 1986 to December 2011 in 17 different centres worldwide were evaluated. Fifty-five per cent of the patients were female. The median age at diagnosis was 62 (range 28-88) years. Only 9% had a history of exposure to toxic substances, while about 45% of the patients had a history of smoking...
July 7, 2015: Hematological Oncology
Luca Ceriani, Maurizio Martelli, Pier Luigi Zinzani, Andrés J M Ferreri, Barbara Botto, Caterina Stelitano, Manuel Gotti, Maria Giuseppina Cabras, Luigi Rigacci, Livio Gargantini, Francesco Merli, Graziella Pinotti, Donato Mannina, Stefano Luminari, Anastasios Stathis, Eleonora Russo, Franco Cavalli, Luca Giovanella, Peter W M Johnson, Emanuele Zucca
The International Extranodal Lymphoma Study Group (IELSG) 26 study was designed to evaluate the role of (18)F-fluorodeoxyglucose (18FDG) positron emission tomography/computed tomography (PET/CT) in the management of primary mediastinal (thymic) large B-cell lymphoma (PMBCL). We examined the prognostic impact of functional PET parameters at diagnosis. Metabolic activity defined by the maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) was measured on baseline 18FDG PET/CT following a standard protocol in a prospectively enrolled cohort of 103 PMBCL patients...
August 20, 2015: Blood
Carlo Messina, David Christie, Emanuele Zucca, Mary Gospodarowicz, Andrés J M Ferreri
Recent studies have contributed to the enhancement of clinical and molecular knowledge on bone lymphomas, a group of rare malignancies with particular characteristics. Nevertheless, several questions remain unanswered and the level of evidence supporting some diagnostic and therapeutic decisions remains low. Currently, three different forms of bone lymphomas can be distinguished: the primary bone lymphoma, consisting of a single bone lesion with or without regional lymphadenopathies; the polyostotic lymphoma, consisting of multifocal disease exclusively involving the skeleton; and the disseminated lymphoma with secondary infiltration of the skeleton...
March 2015: Cancer Treatment Reviews
Maurizio Martelli, Luca Ceriani, Emanuele Zucca, Pier Luigi Zinzani, Andrés J M Ferreri, Umberto Vitolo, Caterina Stelitano, Ercole Brusamolino, Maria Giuseppina Cabras, Luigi Rigacci, Monica Balzarotti, Flavia Salvi, Silvia Montoto, Armando Lopez-Guillermo, Erica Finolezzi, Stefano A Pileri, Andrew Davies, Franco Cavalli, Luca Giovanella, Peter W M Johnson
PURPOSE: To assess the role of [18F]fluorodeoxyglucose ([18F]FDG) positron emission tomography/computed tomography (PET/CT) after rituximab and anthracycline-containing chemoimmunotherapy in patients with primary mediastinal large B-cell lymphoma (PMLBCL). PATIENTS AND METHODS: Among 125 patients prospectively enrolled, 115 were eligible for central review of PET/CT scans at the completion of standard chemoimmunotherapy, by using a five-point scale. Consolidation radiotherapy (RT) was permitted and given to 102 patients...
June 10, 2014: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Marta Bruno Ventre, Andrés J M Ferreri, Mary Gospodarowicz, Silvia Govi, Carlo Messina, David Porter, John Radford, Dae Seog Heo, Yeon Park, Giovanni Martinelli, Emma Taylor, Helen Lucraft, Angela Hong, Lydia Scarfò, Emanuele Zucca, David Christie
INTRODUCTION: The clinical features, management, and prognosis of stage I-II diffuse large B-cell lymphoma of the bone (PB-DLBCL) included in an international database of 499 lymphoma patients with skeletal involvement were reviewed. METHODS: HIV-negative patients (n = 161) with diffuse large B-cell lymphoma of the bone (PB-DLBCL) after complete staging workup were considered. The primary objective of this study was to identify the most effective treatment modality; the secondary objectives were to define the contribution of irradiation fields and doses and the pattern of relapse...
March 2014: Oncologist
Carlo Messina, Andrés J M Ferreri, Silvia Govi, Marta Bruno-Ventre, Elías A Gracia Medina, David Porter, John Radford, Dae S Heo, Hee Y Park, Barbara Pro, Jayasingham Jayamohan, Carlo Visco, Lydia Scarfò, Emanuele Zucca, Mary Gospodarowicz, David Christie
'Multifocal bone lymphoma' or 'polyostotic lymphoma' is a neoplasm with exclusive multifocal involvement of the skeleton, without affecting lymph nodes or other soft tissues. Knowledge on this uncommon condition is limited because the related literature is sparse and fragmentary. We reviewed cases of multifocal bone diffuse large B-cell lymphoma (MB-DLBCL) registered in a clinico-pathological database of the International Extranodal Lymphoma Study Group that includes 499 cases of bone lymphoma. Clinical features, management and prognosis of 37 MB-DLBCL patients and 63 'controls' (stage-IV DLBCL and skeletal involvement) were analysed...
March 2014: British Journal of Haematology
Silvia Govi, David Christie, Silvia Mappa, Emerenziana Marturano, Marta Bruno-Ventre, Carlo Messina, Elías A Gracia Medina, David Porter, John Radford, Dae Seog Heo, Yeon Park, Barbara Pro, Jayasingham Jayamohan, Nick Pavlakis, Emanuele Zucca, Mary Gospodarowicz, Andrés J M Ferreri
Indolent lymphomas primarily involving the skeleton (iPBL) represent < 1% of all primary bone lymphomas. The management and prognosis have not been previously described. Patients with primary and secondary iPBL were selected from an international database of 499 patients with a histopathological diagnosis of non-Hodgkin lymphoma and skeleton involvement, and clinical features, management and prognosis were analyzed. Twenty-six (5%) patients had an iPBL. Ten patients had small lymphocytic lymphoma, 10 had follicular lymphoma and six had lymphoplasmacytic lymphoma...
August 2014: Leukemia & Lymphoma
M Mian, D Capello, M B Ventre, D Grazio, M Svaldi, A Rossi, R Tsang, M K Gospodarowicz, E Oldani, M Federico, S Luminari, L Marcheselli, E M Pogliani, F Rossini, M E Cabrera, M Martelli, G Gutierrez-Garcia, M Busetto, C Visco, M Fiegl, D Rossi, G Gaidano, F Cavalli, E Zucca, A Rambaldi, S Cortelazzo
It is known that extranodal head and neck diffuse large B cell lymphomas (eHN-DLBCL) can affect various anatomical structures what is not well-known, however, is whether they differ in terms of clinical presentation and outcome. Clinical data of the multi-institutional series, the largest of its kind as yet, has been analysed with the aim of answering these open questions and providing long-term follow-up information. Data from 488 patients affected by stage I/II eHN-DLBCL was collected: 300 of the Waldeyer's Ring (WR), 38 of the parotid and salivary glands (PSG), 48 of the thyroid gland (TG), 53 of the nasal cavity and paranasal sinuses (NPS), 24 of the palate and oral cavity (POC) and 25 with more than one involved site...
August 20, 2013: Annals of Hematology
Miaoxia He, Changjing Zuo, Jianjun Wang, Jianmin Liu, Binghua Jiao, Jianmin Zheng, Zailong Cai
BACKGROUND: Primary central nervous system lymphomas, predominantly diffuse large B-cell lymphomas (PCNS-DLBCL), are aggressive malignancies, and no histopathological variables with independent prognostic value are currently available. The aim of this study is to determine the prognostic value of histopathological variables of PCNS-DLBCL. METHODS: Aggregative perivascular tumor cells (APVTs) and reactive perivascular T cell infiltrates (RPVIs) in tumor samples from 62 immunocompetent patients with PCNS-DLBCL were histopathologically and immunohistochemically studied...
June 2013: Neuro-oncology
Emanuele Zucca, Annarita Conconi, Daniele Laszlo, Armando López-Guillermo, Reda Bouabdallah, Bertrand Coiffier, Catherine Sebban, Fabrice Jardin, Umberto Vitolo, Franck Morschhauser, Stefano A Pileri, Christiane Copie-Bergman, Elias Campo, Andrew Jack, Irene Floriani, Peter Johnson, Maurizio Martelli, Franco Cavalli, Giovanni Martinelli, Catherine Thieblemont
PURPOSE: Apart from localized gastric disease, there is no consensus on standard initial treatment of mucosa-associated lymphoid tissue lymphoma. The IELSG-19 study (Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in MALT Lymphoma) was launched to compare chlorambucil alone versus chlorambucil plus rituximab in patients not previously given systemic anticancer therapy. PATIENTS AND METHODS: Patients not responding to or not suitable for local therapy were eligible...
February 10, 2013: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Christiane Copie-Bergman, Andrew C Wotherspoon, Carlo Capella, Teresio Motta, Ennio Pedrinis, Stefano A Pileri, Francesco Bertoni, Annarita Conconi, Emanuele Zucca, Maurilio Ponzoni, Andrés J M Ferreri
The International Extranodal Lymphoma Study Group (IELSG) promoted this study to determine the inter-observer agreement in the application of the Groupe d' Etude des Lymphomes de l' Adulte (GELA) histological scoring system for evaluating residual disease in post-treatment gastric biopsies of patients with gastric Mucosa-Associated Lymphoid Tissue (MALT) lymphoma (GML). Twenty-one patients with Helicobacter pylori -associated GML and treated with anti-H. pylori therapies were considered. A total of 154 biopsy sets from follow-up endoscopic procedures after H...
January 2013: British Journal of Haematology
Hervé Ghesquières, Youenn Drouet, Marie Pierre Sunyach, Catherine Sebban, Catherine Chassagne-Clement, Emmanuel Jouanneau, Jérome Honnorat, Pierre Biron, Jean Yves Blay
Long-term primary CNS lymphoma (PCNSL) survivors could have multiple adverse prognostic factors at diagnosis such as age, performance status (PS), site of the tumour (deep vs superficial), lactate dehydrogenase (LDH) level and CSF protein level. Whether these five prognostic factors integrated in the International Extranodal Lymphoma Study Group (IELSG) score have a time-dependent effect is questionable. Among 132 PCNSL patients treated at our institution between 1984 and 2006, 91 available patients for IELSG score were evaluated by time-segmented analysis...
June 2013: Hematological Oncology
Michael Mian, Andrés J M Ferreri, Andrea Rossi, Annarita Conconi, Richard Tsang, Mary K Gospodarowicz, Elena Oldani, Massimo Federico, Stefano Luminari, Enrico M Pogliani, Fausto Rossini, Maria E Cabrera, Maurizio Martelli, Gonzalo Gutierrez-Garcia, Mario Busetto, Franco Cavalli, Emanuele Zucca, Alessandro Rambaldi, Sergio Cortelazzo
Consolidation radiotherapy (cRT) in patients with stage I/II diffuse large B-cell lymphoma of the Waldeyer's ring (WR-DLBCL) in complete remission (CR) after induction chemotherapy (CHT) is often associated with relevant acute and chronic toxicity, and its impact on survival remains to be defined. A total of 184 patients in CR after anthracycline-based chemotherapy were retrospectively analyzed: 62 underwent CHT alone (CHT group), while 122 (66%) patients were referred to cRT (CHT + RT group). After a median follow-up of 54 months, 36 patients (20%) experienced relapse: 19% in the CHT group and 20% in the CHT + RT group...
January 2013: Leukemia & Lymphoma
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"